CoChat
Sign Up
Cited by 47Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentNeuroethics, Human Enhancement, Biomedical Innovations

A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study

Open access
Mattos, Paulo, Louzã, Mário Rodrigues, Palmini, André Luís Fernandes, Oliveira, Irismar Reis de, Rocha, Fábio Lopes·2013·Journal of Attention Disorders
DOI 10.1177/1087054711434772
Open this paper in CoChat — free account

Abstract

UNLABELLED: The available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD. OBJECTIVE: To assess the effectiveness of methylphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. METHOD: A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted. RESULTS: Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p < .0001), as well as the Total AAQoL (p < .0001). A significant reduction on Clinical Global Impression-Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p < .0001). No serious adverse event was reported. CONCLUSION: Treatment of adult ADHD patients with OROS MPH improves QoL.

Integrity signals

Registry

Crossref · 10.1177/1087054711434772

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In women, comorbid anxiety and depressive disorders can obscure underlying ADHD or lead to misdiagnosis.

    “in women, the clinical picture is often complicated by comorbid anxiety and depressive disorders. These symptoms, being more “visible” to clinicians, can obscure underlying ADHD or lead to misdiagnosis”

    From ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives (2025) · cites this paper as [39]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Mattos, P., Louzã, M. R., Palmini, A. L. F., Oliveira, I. R. D., & Rocha, F. L.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Faculdade de Medicina da Universidade de São Paulo, Brazil
  • Pontifícia Universidade Católica do Rio Grande do Sul (BR)
  • Universidade Federal da Bahia (BR)
  • Instituto de Previdência dos Servidores do Estado de Minas Gerais, Brazil
ORCID
Venue
Journal of Attention Disorders
Publisher
SAGE Publications
Published
2012-02-14
Volume
17
Issue
5
Pages
444-448
ISSN
  • 1087-0547 (ISSN-L)
  • 1557-1246
DOI
10.1177/1087054711434772
OpenAlex
W2040655116
Cited by
47
References
17
Citations by year
2025: 3 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 9 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 6 · 2014: 7 · 2013: 2
FWCI
3.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Attention Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
Funders
Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neuroethics, Human Enhancement, Biomedical Innovations
Keywords
adult ADHD, OROS methylphenidate, quality of life, ADHD medication, anxiety, depression, treatment effectiveness, adverse events
MeSH terms
Adult, Central Nervous System Stimulants, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Brazil, Delayed-Action Preparations, Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Methylphenidate, Personality Inventory, Quality of Life, Comorbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review